Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu; diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; poliovirus, quantity: 29 dagu - injection, suspension - excipient ingredients: aluminium phosphate; formaldehyde; polysorbate 80; neomycin; water for injections; phenoxyethanol; streptomycin sulfate; polymyxin b sulfate; glutaral; ethanol - adacel polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.,children 4-6 years of age should have already received four doses of dtpa and ipv or opv.,adacel polio is not intended for primary immunisation.,adacel polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.,the use of adacel polio should be determined on the basis of official recommendations. for further information, refer to the current immunisation handbook.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - diphtheria toxoid; tetanus toxoid; pertussis toxoid (pt); haemophilus influenza type b conjugate to; pertactin (69 kda outer membrane protein-69k); inactivated polio virus type 3; inactivated polio virus type 2; inactivated polio virus type 1; filamentous haemagglutinin (fha); r-dna hepatitis b antigen -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - diphtheria toxoid; tetanus toxoid; pertussis toxoid (pt); pertactin (69 kda outer membrane protein-69k); inactivated polio virus type 3; inactivated polio virus type 2; inactivated polio virus type 1; filamentous haemagglutinin (fha) -

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - quadracel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. a single dose of quadracel is approved for use as a fifth dose in the diphtheria, tetanus, pertussis (dtap) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (ipv) vaccination series in children 4 through 6 years of age whose previous dtap vaccine doses have been with pentacel® [diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine], daptacel® (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) and/or vaxelis (diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis b vaccine). severe allergic reaction (e.g., anaphylaxis) to any ingredient of quadracel [see description (11) ] or following any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, or inactivated poliovi

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - tetanus toxoid, quantity: 40 iu; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 80 dagu; pertussis fimbriae 2 + 3, quantity: 5 microgram; haemophilus influenza type b polyribose ribitol phosphate, quantity: 3 microgram; pertussis toxoid, quantity: 20 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram; hepatitis b surface antigen, quantity: 10 microgram; pertactin, quantity: 3 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; dibasic sodium phosphate; monobasic sodium phosphate - vaxelis (dtpa5-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).,the use of vaxelis should be in accordance with official recommendations.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid; tetanus toxoid; pertussis toxoid; filamentous haemagglutinin (fha); pertactin; type 1 (mahoney); type 2 (mef-1); type 3 (saukett) - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - diphtheria-pertussis-poliomyelitis-tetanus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated gumboro virus; inactivated newcastle disease virus antigen - misc. vaccines or anti sera - inactivated gumboro virus biological-virus active 0.0 vnu/dose; inactivated newcastle disease virus antigen vaccine-viral active 0.0 hi/dose - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - infectious bursal disease | newcastle disease | bursal disease

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated infectious bursal disease virus (strain d78) - misc. vaccines or anti sera - inactivated infectious bursal disease virus (strain d78) vaccine-viral active 0.0 p - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - infectious bursal disease | bursal disease

Israel - English - Ministry of Health

sanofi israel ltd - poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated - suspension for injection - poliovirus type 1 inactivated 40 u/vial; poliovirus type 2 inactivated 8 u/vial; poliovirus type 3 inactivated 32 u/vial - poliomyelitis vaccines - prophylaxis of poliomyelitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - inactivated rabies virus - powder and solvent for solution for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus